Document is current

Article History

Received: 5 February 2024

Revised: 5 September 2024

Accepted: 20 September 2024

First Online: 8 October 2024

Competing interests

: KYCT: Consultancy fees, honorarium, travel support and speaker fees from Bayer, Novartis, Boehringer Ingelheim, Roche, Topcon and Carl Zeiss AG, outside the submitted work. Member of the Eye editorial board. PL: Consultant for Aerie, AbbVie, Apellis, Bausch & Lomb, Bayer, Biogen, Boehringer Ingelheim, Genentech, Novartis, Ocular Therapeutix, Outlook Therapeutics and Roche. BE: Consultant for Allergan, Bayer, Novartis and Roche. AJ: Personal fees from Novartis, Bayer HealthCare Pharmaceuticals, Allergan and Boehringer Ingelheim, as well as grants from Novartis and Bayer HealthCare Pharmaceuticals. AK: AbbVie, Alcon, Apellis, Bayer, Boehringer Mannheim, Carl Zeiss Meditec, Heidelberg, Janssen, Nikon-Optos, Novartis, Roche and Topcon. J-FK: Consultant for Allergan/AbbVie, Apellis, Bayer, Carl Zeiss Meditec, Janssen, Nano Retina, Roche and Théa, and is a member of the Data and Safety Monitoring Boards for Alexion and Novo Nordisk. XL: No financial interests to report. AL: Consultant for Allergan, Annexon, Bayer Healthcare, Beyeonics, Biogen, ForSight Labs, IQVIA, Iveric Bio, Johnson & Johnson, MJH Events, Nano Retina, Notal Vision, Novartis, Ocuphire Pharma, OcuTerra, OphtiMedRx, Roche, Ripple Therapeutics, Syneos, WebMD and Xbrane. ML-A: Consultant for Allergan/AbbVie, Apellis, Bayer, Novartis, Roche and Santen. RN: Honoraria for consultancy and lecture fees from Bayer HealthCare Pharmaceuticals and Allergan. AAO: Personal fees from AbbVie Japan, Inc., grants and personal fees from Alcon Pharma KK (Japan), personal fees from Astellas Japan, personal fees from Bayer AG, grants and personal fees from Bayer Yakuhin Ltd. (Japan), personal fees from Daiichi-Sankyo, grants and personal fees from Mitsubishi Tanabe Pharma Corporation, personal fees from Senju Pharmaceutical Co., Ltd., and grants and personal fees from Santen Pharmaceutical Co. Ltd. (Japan). IP: Consultancy, travel and speaker fees from Allergan, Bayer, Novartis and Roche. FR: Consultant for Bayer, Iveric Bio, Johnson & Johnson, Novartis and Roche. DW: Consultant for AbbVie, Alcon, Apellis, Bayer, Bausch Health, Biogen, Boehringer Ingelheim, Novartis, Ripple Therapeutics, Roche, Topcon and Zeiss, has received financial support (to institution) from Bayer, Novartis and Roche, and is an equity owner at ArcticDx. LW: Consultant for Bayer, Lumibird Medical, Novartis and Roche. DZ: Received grants from Roche, has served on scientific advisory boards for AbbVie, Allergan, Bayer, Johnson & Johnson, Novartis and Roche, and has been a speaker for AbbVie, Allergan, Bayer, Novartis and Roche. JZ-V: Received grants from AbbVie, Allergan, Bayer, Novartis and Roche, has served on scientific advisory boards for AbbVie, Allergan, Bayer, Novartis and Roche, and has been a speaker for AbbVie, Alcon, Alimera Sciences, Allergan, Bausch & Lomb, Bayer, Brill Pharma, DORC, Esteve, Novartis, Roche, Topcon Healthcare and Zeiss. Member of the Eye editorial board. PM: Received consulting fees from Allergan, Apellis, Bayer, Novartis, and Roche, lecture honoraria from Bayer, support for attending meetings and/or travel from Bayer and Roche, and he is a member of data safety monitoring boards or advisory boards for Apellis and Bayer. VC: Advisory board member for Alcon, Roche, Bayer, Novartis, Apellis and Boehringer Ingelheim, and received grants from Bayer, Novartis and Roche. Member of the Eye editorial board.